These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 29093151)

  • 1. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
    Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
    J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
    Harrold LR; Reed GW; Solomon DH; Curtis JR; Liu M; Greenberg JD; Kremer JM
    Arthritis Res Ther; 2016 Dec; 18(1):280. PubMed ID: 27906048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA.
    Harrold LR; Bryson J; Lehman T; Zhuo J; Gao S; Han X; Schrader A; Rebello S; Pappas DA; Sommers T; Kremer JM
    Rheumatol Ther; 2021 Jun; 8(2):937-953. PubMed ID: 34047953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry.
    Harrold LR; Litman HJ; Connolly SE; Alemao E; Kelly S; Rebello S; Hua W; Kremer JM
    Rheumatol Ther; 2019 Jun; 6(2):217-230. PubMed ID: 30868550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
    Jin Y; Kang EH; Brill G; Desai RJ; Kim SC
    J Rheumatol; 2018 Aug; 45(9):1240-1248. PubMed ID: 29764964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive.
    Harrold LR; Wittstock K; Kelly S; Han X; Zhuo J; Schrader A; Middaugh N; Moore PC; Khaychuk V
    Adv Rheumatol; 2024 Jan; 64(1):10. PubMed ID: 38243281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M; Kaneko Y; Kondo H; Takeuchi T
    Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
    Wei W; Knapp K; Wang L; Chen CI; Craig GL; Ferguson K; Schwartzman S
    Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
    Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
    Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
    Shin A; Park EH; Dong YH; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
    Osteoporos Int; 2020 Nov; 31(11):2131-2139. PubMed ID: 32514765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.
    Monti S; Klersy C; Gorla R; Sarzi-Puttini P; Atzeni F; Pellerito R; Fusaro E; Paolazzi G; Rocchetta PA; Favalli EG; Marchesoni A; Caporali R
    Clin Rheumatol; 2017 Apr; 36(4):753-761. PubMed ID: 28058538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
    Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
    Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis.
    Wunderlich C; Oliviera I; Figueiredo CP; Rech J; Schett G
    Semin Arthritis Rheum; 2017 Jun; 46(6):709-714. PubMed ID: 28109618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?
    Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
    Clin Rheumatol; 2017 Jun; 36(6):1215-1220. PubMed ID: 28251392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
    Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
    Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.
    Harrold LR; Reed GW; Kremer JM; Curtis JR; Solomon DH; Hochberg MC; Greenberg JD
    Ann Rheum Dis; 2015 Feb; 74(2):430-6. PubMed ID: 24297378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.